Is treatment of hypercholesterolemia optimal? Results of the survey assessing ambulatory treatment of hypercholesterolemia in Poland;Czy pacjenci z hipercholesterolemia̧ sa̧ leczeni optymalnie? Wyniki badania oceniaja̧cego stan leczenia hipercholesterolemii w warunkach ambulatoryjnych w Polsce

Polski Przeglad Kardiologiczny

Volumn 12, Issue 3, 2010, Pages 207-211

  Michalak, Marcin ^a   Kołtowski, Łukasz ^a   Jaworski, Rafał ^b   Filipiak, Krzysztof J ^a  

^a WARSZAWSKI UNIWERSYTET MEDYCZNY   (Poland)

^b MSD Polska Sp Z o o ^*  (Poland)

Author keywords

Cholesterol; Ezetimibe; Hypercholesterolemia; LDL C; Statins

Indexed keywords

ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ACUTE CORONARY SYNDROME; AMBULATORY CARE; ARTICLE; DIABETES MELLITUS; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; POLAND; QUESTIONNAIRE; STABLE ANGINA PECTORIS;

EID: 78649686875     PISSN: 15075540     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Daniels TF, Killinger KM, Michal JJ, i wsp. Lipoproteins, cholesterol homeostasis and cardiac health. Int J Biol Sci. 2009;5:474-488.
2. O'Keefe JH Jr, Cordain L, Harris WH, i wsp. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142-2146.
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
4. Graham I, Atar D, Borch-Johnsen K, i wsp. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2007;28:2375-2414.
5. Brugts JJ, Yetgin T, Hoeks SE, i wsp. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
6. Baigent C, Keech A, Kearney PM, i wsp. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
7. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart. 2007;93:914-921.
8. Ridker PM, Danielson E, Fonseca FA, i wsp. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
9. Foley KA, Simpson RJ Jr, Crouse JR 3rd, i wsp. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol. 2003;92:79-81.
10. Pearson TA, Laurora I, Chu H, i wsp. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467.
11. Ballantyne CM, Houri J, Notarbartolo A. Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia. Circulation. 2003;107:2409-2415.
12. Pietrasik A, Starczewska M, Główczyńska R, i wsp. Prewencja wtórna zawału serca w warunkach podstawowej opieki zdrowotnej w Polsce - wybrane wyniki programu POLKARD-SPOK. Kardiol Pol. 2006;64 Suppl. 3.
13. Pedersen TR, Kjekshus J, Berg K, i wsp. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
14. Sacks FM, Pfeffer MA, Moye LA, i wsp. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
15. LaRosa JC, Grundy SM, Waters DD, i wsp. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
16. LaRosa JC, Grundy SM, Kastelein JJ, i wsp. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol. 2007;100:747-752.
17. Cannon CP, Braunwald E, McCabe CH, i wsp. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
18. Insull J, Ghalal JK, Hassman DR. Achieving Low-Density Lipoprotein Cholesterol Goals in High-Risk Patients in Managed Care: Comparison of Rosuvastatin, Atorvastatin, and Simvastatin in the SOLAR Trial. Mayo Clin Proc. 2007;82:543-550.